Home > Reviews > PT-141 Review
PT-141 Review 2025: Research Grade Analysis
Last Updated: February 2025 | By CellForce Labs Research Team | Contains affiliate links
PT-141 Quick Summary
PT-141 (Bremelanotide) is a synthetic melanocortin peptide that acts on the MC4 receptor in the central nervous system. It is unique among peptides in its class as it works through neural pathways rather than the vascular system. PT-141 received FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women, giving it one of the strongest clinical evidence bases of any research peptide.
Disclaimer: CellForgeLabs.com provides information for research purposes only. Products linked are for laboratory research only, not for human consumption. This page contains affiliate links.
Quick Navigation
What is PT-141?
PT-141 is a cyclic heptapeptide (7 amino acid) derived from the alpha-melanocyte stimulating hormone (alpha-MSH) analog Melanotan II. While Melanotan II activates multiple melanocortin receptors (causing tanning, appetite suppression, and sexual effects), PT-141 was developed as a more selective compound focused on MC3 and MC4 receptor activation. Its mechanism of action is unique in that it works centrally through the hypothalamus rather than peripherally through vascular mechanisms. The FDA approved PT-141 as Vyleesi in June 2019, providing robust clinical safety and efficacy data.
| Category | Melanocortin / Sexual Function |
| Also Known As | PT 141, Bremelanotide |
| Research Status | FDA-approved (Vyleesi), clinical data |
| Key Function | Melanocortin-4 receptor agonist |
| Half-Life | ~2.7 hours |
Research Benefits of PT-141
- Central Mechanism: Works through neural pathways in the hypothalamus, distinct from vascular-acting compounds.
- FDA Approval: Approved in 2019 as Vyleesi, providing extensive clinical trial data on safety and efficacy.
- Sexual Function Research: Demonstrated significant improvement in desire scores in clinical trials.
- Non-Vascular: Does not affect blood pressure or cardiovascular function significantly at standard doses.
- Novel Mechanism: First compound in its class to work through melanocortin receptor pathways.
Mechanism of Action
PT-141 activates melanocortin-3 and melanocortin-4 (MC3R/MC4R) receptors in the hypothalamus and limbic system. MC4R activation in the paraventricular nucleus triggers downstream signaling through oxytocin and dopamine pathways. This central mechanism is fundamentally different from vascular-acting compounds and represents a novel pharmacological approach targeting the neural circuitry of desire and arousal rather than peripheral physiology.
Research Protocols
| Parameter | Research Data |
|---|---|
| Research Dose | 1-2mg subcutaneous |
| Administration | Subcutaneous injection |
| Onset | ~45 minutes to 2 hours |
| Duration | ~6-12 hours |
| Frequency | As needed (not daily) |
| Max Frequency | FDA label: once per 24 hours, max 8x/month |
Visit our Reconstitution Calculator for dosing calculations.
Side Effects & Safety Profile
Clinical trial data from FDA approval provides detailed safety information. The most common side effects include nausea (40% of subjects, usually mild), flushing (20%), headache (11%), and injection site reactions. Nausea is typically transient and dose-dependent. PT-141 can cause transient increases in blood pressure, so monitoring is recommended. Darkening of skin on the face and gums has been reported with repeated use. The FDA label recommends limiting use to once per 24 hours and no more than 8 doses per month.
Where to Buy PT-141
| Vendor | Price | Testing | Rating | Link |
|---|---|---|---|---|
| Swiss Chems | $44.95 (10mg) | 3rd-party HPLC + MS | 4.8/5 | Buy → |
| Peptide Sciences | $49.99 (10mg) | 3rd-party HPLC | 4.7/5 | Buy → |
| Amino Asylum | $34.99 (10mg) | In-house | 4.3/5 | Buy → |
Source Verified PT-141
Third-party tested with HPLC and mass spectrometry verification.
Related Research
Frequently Asked Questions
Is PT-141 FDA approved?
Yes, PT-141 (bremelanotide) was FDA approved in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.
How does PT-141 work?
PT-141 works centrally through melanocortin-4 receptors in the hypothalamus, activating neural pathways related to desire through oxytocin and dopamine signaling. This is distinct from vascular-acting compounds.
Disclosure: CellForgeLabs.com is an affiliate site. We earn commissions from qualifying purchases. All products referenced are for laboratory research purposes only.